Incyte is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, and

Morges, Switzerland Morges (; la, Morgiis, plural, probably ablative, else dative; frp, Môrges) is a municipality in the Swiss canton of Vaud and the seat of the district of Morges. It is located on Lake Geneva. History Morges is first mentioned in 1288 as '' ...

. The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 and Incyte Genomics, Inc. of Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia. Incyte Corporation currently develops and manufacturers prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity.

History

In 2014, Incyte named Hervé Hoppenot president and CEO, and in 2015 he was appointed chairman of the Board of Directors. Hoppenot had previously served as the president of Novartis Oncology; he had been with Novartis since 2003. In September 2015, the company announced it had gained exclusive development and commercial right pertaining to Jiangsu Hengrui Medicine Co., Ltd's anti-PD-1 monoclonal antibody, SHR-1210, in a deal worth $795+ million. In January 2020, Incyte signed a collaboration and license agreement for the global development and commercialization of tafasitamab with MorphoSys. On March 3, 2020, the agreement received antitrust clearance and thus became effective.

Pharmaceuticals

Incyte Corporation currently has seven marketed and co-marketed pharmaceutical products, including Jakafi (ruxolitinib), Pemazyre (pemigatinib), Monjuvi (tafasitamab-cxix) , Opzelura (

Ruxolitinib Ruxolitinib, sold under the brand names Jakafi and Jakavi, is a medication used for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow; polycythemia vera (PCV), when there ...

), Tabrecta (capmatinib), Olumiant (Baricitinib), and Iclusig (ponatinib). In 2013, Novartis acquired Incyte's

c-Met inhibitor c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF). These inhibitors may have therapeutic application in the treatment ...

capmatinib Capmatinib, sold under the brand name Tabrecta, is a medication for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to the exon 14 skipping of the ''MET'' gene, which codes for th ...

(INC280, INCB028060), which is marketed under the brand name Tabrecta. As of 2014, the company was developing baricitinib, an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly. It gained EU approval in February 2017. In April 2017, the US FDA issued a rejection, citing concerns about dosing and safety. In May 2018, baricitinib was approved in the United States for the treatment of rheumatoid arthritis under the brand name Olumiant. As of 2016 epacadostat, an indoleamine 2,3-dioxygenase (IDO1) inhibitor, was in development for various cancers and was in combination trials with

Merck Merck refers primarily to the German Merck family and three companies founded by the family, including: * the Merck Group, a German chemical, pharmaceutical and life sciences company founded in 1668 ** Merck Serono (known as EMD Serono in the Unite ...

's pembrolizumab (Keytruda) and

Bristol Myers Squibb The Bristol Myers Squibb Company (BMS) is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the ''Fortune'' 500 list of the lar ...

's nivolumab (Opdivo).

References

External links

{{Authority control American companies established in 1991 Companies based in New Castle County, Delaware Pharmaceutical companies established in 1991 Companies listed on the Nasdaq 1991 establishments in California Pharmaceutical companies of the United States Life sciences industry Health care companies based in Delaware 1993 initial public offerings